kalil, a principal investigator in this drug trial. dr. kalil, dr.with us as well, our doctor on duty for this hour. i want to invite dr. patel into the conversation. i know you've been a bit curious about the timing of this news, dr. patel. so go ahead and jump in with the question here. >> absolutely. dr. kalil, thank you for pushing on the need for scientific rigor during a crisis time like a pandemic. can you tell us a little bit more while we're waiting for the full publication to come out on the timing of the results? there's a lot of chatter about the kind of information that was released yesterday as well as the lancit study. could you comment on the timing of the results? >> sure. the results were from a european group in conjunction with gilead. we at the university of nebraska, at nih, that trial was also randomized trial, run in china at the beginning of the outbreak. but the trial was for about 500 patients. they end up enrolling a little over 200 patients. the problem with that trial is that once you can enroll the patients that are sup

kalil, grateful to you and your colleagues for undertaking these tests. let's hope it works around brings down the coronavirus and saves lives in the process as well. thank you so much for joining us. >> thank you, appreciate it. >>> thank you, coming up. we will take you to ohio where some business leaders are frustrated and rather upset with the republican governor's rather slow approach to re-opening. and our family needs help. right now they're facing a crisis. and they're counting on your takeout and delivery orders to help them through. because if we don't treat restaurants like family today.. they might not be around to treat us like family tomorrow. grubhub. together, we can help save the restaurants we love. . >>> this week the trump's administration's distancing guidelines are expiring tonight. that i hope to restart some businesses in ohio. they want ohio's governor dewine to speed up reports. >> i stay it's frustrating. >>th. >> reporter: her bar and dining room is closed if time after they were ordered to close march 15th. since then she's ha

kalil turned out to be very productive because of thousand patients later, at 68 centers around theers, europe, and asia, remdesivir has been shown to decrease recovery time, which is crucial in s fighting a virus. it decreased recovery time from 14 to 11 days. that shows its decreasing viral replication in the body looks like. it also decreased death rate. something else we are excited about. these are hospital patients, very sick, they have lung problems and they are responding, it looks like, majority of cases to remdesivir. when it's used earlier, we might even see more dramatic results. so the doctor was predictive here. this is the kind of research that we look for, this is the kind of studies we look for, expensive. we now have a new arrow in our quiver. when it comes to vaccines tonight, we also have some good newse because, you know what, we are at an unprecedented place with vaccines. vaccines usually take years to produce, but we have new technologies now. we have genetic-based vaccines we never used before. we understand viruses better and partnering with a company in germ

kalil, and your team, thank you for killing yourself to get this research done so soon. thank you, sir. god bless you and your family. stay healthy. >> thank you, it's a team effort, investigators all over the world. it's a huge team effort. university of nebraska. it's really an effort of so many people. and i cannot thank everyone here, but it's just the beginning. we're going to find more treatments and more things that hopefully will improve the lives of all these patients being affected by the disease. thanks so much for the opportunity, chris. >> doctor, thank you, it made a big difference, i can't get a better source for my audience than you. be well. appreciate it. quick sum-up. we finally have a tool in the box. we're losing way too many people. you know the ratio of people who go on ventilators to get off? it's not good. in fact it's shockingly bad. now there's something that maybe will help. it's for the worst cases, the moderate to severe in the hospital. at least we have something. now, is it a cause to leave your house and to start being cavalier? no. and i

in november al jazeera filmed tom kalil village in western pa caught after days of torrential rain flooding and landslides entire families here were killed communities surrounded by floodwaters and isolated days later families went out in search of their relatives bodies. many say it was the worst disaster they've seen in our lifetime. we said just say warming oceans are causing unpredictable weather patterns in eastern africa and with more rain expected in the coming days help may be slow coming to these villages and the problems may not be. just there. australia has become the 1st country to make it compulsory for web giants google and facebook to pay for news content the competition watchdog says it will release draft details of a payment plan in july earlier attempts by the government to operate a voluntary scheme for digital platforms to pay traditional media for news content of failed advertising revenue in traditional media has all but collapsed due to the coronavirus lockdown with david vaile is a cyber law expert at the university of new south wales he says the government has been

andre kalil who is running the trials and he's optimistic. >> i think the data that we have available it's promising. >> tucker: two months later that research appears to be bring some fruit. dr. marc siegel rejoined us tonight with an update. dr.? >> tucker, we have good news tonight both on the treatment front and then on the vaccine front. on the treatment front, dr. khalil turned out to be very protective because of thousand patients later at 66 centers around europe and asia, remdesivir is shown to reduce recovery time which is crucial, reducing from 14-11 days which shows its decreasing viral replication in the body. but these are hospitalized patients and they have lung problems and are responding it looks like in a majority of the cases to remdesivir. so dr. khalil was predictive here, and it was a kind of research we looked for in the kind of studies we looked for. we now have a new arrow in our quiver. when it comes to vaccines tonight, we also have some good news because, you know what? we are at an unprecedented place with vaccines. vaccines usually take years to produce b

andrej kalil, thank you for joining us. dr.er hotez, thank you for starting us off tonight. >>> when we come back, the mayor of atlanta is up next on the weekend when georgia tried to reopen some businesses. mayor keisha lance bottoms joins us live from atlanta next. ext. the 3:40 mid-shift migraine medicine. introducing ubrelvy™. it's the migraine medicine for anytime, anywhere a migraine attacks without worrying if it's too late or where you happen to be. one dose of ubrelvy™ can quickly stop a migraine in its tracks within two hours. many had pain relief in one hour. do not take with strong cyp3a4 inhibitors. few people had side effects, most common were nausea and tiredness. ask your provider about ubrelvy™ or access doctors from home with telemedicine. migraines can strike anytime, anywhere. ubrelvy™. the anytime, anywhere migraine medicine. ♪[ siren ] & doug give me your hand! i can save you... lots of money with liberty mutual! we customize your car insurance so you only pay for what you need! only pay for what you need.